These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12132898)

  • 1. Molecular design based on 3D-pharmacophore. Application to 5-HT4 receptor.
    Bureau R; Daveu C; Lemaître S; Dauphin F; Landelle H; Lancelot JC; Rault S
    J Chem Inf Comput Sci; 2002; 42(4):962-7. PubMed ID: 12132898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of two 3D QSAR analyses. application to the study of partial agonist serotonin-3 ligands.
    Bureau R; Daveu C; Baglin I; Sopkova-De Oliveira Santos J; Lancelot JC; Rault S
    J Chem Inf Comput Sci; 2001; 41(3):815-23. PubMed ID: 11410063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definition of a pharmacophore for partial agonists of serotonin 5-HT3 receptors.
    Daveu C; Bureau R; Baglin I; Prunier H; Lancelot JC; Rault S
    J Chem Inf Comput Sci; 1999; 39(2):362-9. PubMed ID: 10192948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative receptor mapping of serotoninergic 5-HT3 and 5-HT4 binding sites.
    López-Rodríguez ML; Morcillo MJ; Benhamú B; Rosado ML
    J Comput Aided Mol Des; 1997 Nov; 11(6):589-99. PubMed ID: 9491351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of 5-HT4R ligands: state of art and clinical applications.
    Bureau R; Boulouard M; Dauphin F; Lezoualc'h F; Rault S
    Curr Top Med Chem; 2010; 10(5):527-53. PubMed ID: 20166943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacophore models for metabotropic 5-HT receptor ligands.
    Bojarski AJ
    Curr Top Med Chem; 2006; 6(18):2005-26. PubMed ID: 17017971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin 5-HT3 and 5-HT4 ligands: an update of medicinal chemistry research in the last few years.
    Modica MN; Pittalà V; Romeo G; Salerno L; Siracusa MA
    Curr Med Chem; 2010; 17(4):334-62. PubMed ID: 20015043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular design based on 3D-pharmacophore. Application to 5-HT subtypes receptors.
    Bureau R; Daveu C; Lancelot JC; Rault S
    J Chem Inf Comput Sci; 2002; 42(2):429-36. PubMed ID: 11911713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT4 receptor ligands: applications and new prospects.
    Langlois M; Fischmeister R
    J Med Chem; 2003 Jan; 46(3):319-44. PubMed ID: 12540230
    [No Abstract]   [Full Text] [Related]  

  • 10. Structure-activity relationships of serotonin 5-HT
    Thirumaran SL; Lepailleur A; Rochais C
    Eur J Med Chem; 2019 Dec; 183():111705. PubMed ID: 31581003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Physiopathological and therapeutic perspectives on the new serotonin receptors: the type 4 receptor].
    Lefebvre H
    Rev Med Interne; 2000 Aug; 21(8):661-3. PubMed ID: 10989490
    [No Abstract]   [Full Text] [Related]  

  • 12. Benzimidazole derivatives. 3. 3D-QSAR/CoMFA model and computational simulation for the recognition of 5-HT(4) receptor antagonists.
    López-Rodríguez ML; Murcia M; Benhamú B; Viso A; Campillo M; Pardo L
    J Med Chem; 2002 Oct; 45(22):4806-15. PubMed ID: 12383006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latest advances towards the discovery of 5-HT(7) receptor ligands.
    Pittala V; Pittala D
    Mini Rev Med Chem; 2011 Nov; 11(13):1108-21. PubMed ID: 22353220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 5-HT4 receptors in guinea-pig colon and rat oesophagus: effects of novel agonists and antagonists.
    Leung E; Pulido-Rios MT; Bonhaus DW; Pekins LA; Zeitung KD; Hsu SA; Clark RD; Wong EH; Eglen RM
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Jul; 354(2):145-56. PubMed ID: 8857591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
    Glen RC; Martin GR; Hill AP; Hyde RM; Woollard PM; Salmon JA; Buckingham J; Robertson AD
    J Med Chem; 1995 Sep; 38(18):3566-80. PubMed ID: 7658443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of 1,2,4-substituted piperazines, new serotonin receptor ligands, with 5-HT1A and 5-HT2A receptors.
    Chilmonczyk Z; Cybulski M; Iskra-Jopa J; Chojnacka-Wójcik E; Tatarczyńska E; Kłodzińska A; Leś A; Bronowska A; Sylte I
    Farmaco; 2002 Apr; 57(4):285-301. PubMed ID: 11989808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site.
    Buchheit KH; Gamse R; Giger R; Hoyer D; Klein F; Klöppner E; Pfannkuche HJ; Mattes H
    J Med Chem; 1995 Jun; 38(13):2326-30. PubMed ID: 7608898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT(4) receptor antagonists: structure-affinity relationships and ligand-receptor interactions.
    López-Rodriguez ML; Benhamú B; Morcillo MJ; Murcia M; Viso A; Campillo M; Pardob L
    Curr Top Med Chem; 2002 Jun; 2(6):625-41. PubMed ID: 12052197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arylpiperazine derivatives acting at 5-HT(1A) receptors.
    López-Rodríguez ML; Ayala D; Benhamú B; Morcillo MJ; Viso A
    Curr Med Chem; 2002 Feb; 9(4):443-69. PubMed ID: 11945120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives.
    Orjales A; Alonso-Cires L; López-Tudanca PL; Tapia I; Labeaga L; Mosquera R
    Drug Des Discov; 2000; 16(4):271-9. PubMed ID: 10807033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.